Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-238

Abstract

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence

Keywords

• Nivolumab
• Ipilimumab
• Melanoma